Cancer Medicine (May 2023)

Cellular and molecular features related to exceptional therapy response and extreme long‐term survival in glioblastoma

  • B. Decraene,
  • M. Vanmechelen,
  • P. Clement,
  • J. F. Daisne,
  • I. Vanden Bempt,
  • R. Sciot,
  • A. D. Garg,
  • P. Agostinis,
  • F. De Smet,
  • S. De Vleeschouwer

DOI
https://doi.org/10.1002/cam4.5681
Journal volume & issue
Vol. 12, no. 10
pp. 11107 – 11126

Abstract

Read online

Abstract Glioblastoma Multiforme (GBM) remains the most common malignant primary brain tumor with a dismal prognosis that rarely exceeds beyond 2 years despite extensive therapy, which consists of maximal safe surgical resection, radiotherapy, and/or chemotherapy. Recently, it has become clear that GBM is not one homogeneous entity and that both intra‐and intertumoral heterogeneity contributes significantly to differences in tumoral behavior which may consequently be responsible for differences in survival. Strikingly and in spite of its dismal prognosis, small fractions of GBM patients seem to display extremely long survival, defined as surviving over 10 years after diagnosis, compared to the large majority of patients. Although the underlying mechanisms for this peculiarity remain largely unknown, emerging data suggest that still poorly characterized both cellular and molecular factors of the tumor microenvironment and their interplay probably play an important role. We hereby give an extensive overview of what is yet known about these cellular and molecular features shaping extreme long survival in GBM.

Keywords